Biocomposites, a privately held international developer, manufacturer and distributor of synthetic tissue-regeneration products with U.S. headquarters in Wilmington, N.C., has received marketing approval for a bone graft product from by the State Food and Drug Administration of the People's Republic of China.
The 12-year-old firm, headquartered in the British city of Keele, Staffordshire, said its Shanghai subsidiary has been given marketing approval for the company's unique bone graft substitute geneX.
Biocomposites says geneX is a synthetic bone graft material designed with a negatively charged surface that stimulates bone cell activity, accelerating bone formation and fusion by harnessing key proteins and directing new bone cells to adhere and proliferate. Ultimately the geneX material is absorbed by the body, replaced by new bone tissue.
Biocomposites has developed several products for the orthopaedics and dentistry markets.